Press Release | NeoGenomics Laboratories

July 27, 2023

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

July 18, 2023

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

June 29, 2023

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

June 15, 2023

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

June 5, 2023

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

June 1, 2023

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

May 30, 2023

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

May 8, 2023

NeoGenomics Reports First Quarter 2023 Results

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients